Investigation of the effects of imeglimin administration on the metabolism of mitochondrial diabetes mellitus

Investigation of the effects of imeglimin administration on the metabolism of mitochondrial diabetes mellitus - Investigation of the effects of imeglimin administration on the metabolism of mitochondrial diabetes mellitus

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000053289

Enrollment

Registered

2024-01-08

Start date

2021-12-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

mitochondrial diabetes

Interventions

The dosage was gradually increased from 500 mg of imeglimine to a maximum dosage of 2000 mg in 8 weeks. To confirm the efficacy of the combination, 1 mg of glimepiride, 5 mg of linagliptin, and 10 mg

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Mitochondrial diabetic patients who consented to participate in the study

Exclusion criteria

Exclusion criteria: nothing

Design outcomes

Primary

Measure	Time frame
Improvement of HbA1c 12 weeks after the start of administration	—

Countries

Japan

Contacts

Public ContactHIRAYAMA KIICHI

Kimitsu Chuo Hospital Department of Medicine, Division of Diabetes, Endocrinology and Metabolism

m14097kh@jichi.ac.jp+81-438-36-1071

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026